Diagnostic Challenges and Solutions in Systemic Amyloidosis
International Journal of Molecular Sciences · 28.02.2023 · 24 (5) · 4655
DOI: 10.3390/ijms24054655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2023. Verfasst von Rivka Goldis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amyloidosis refers to a clinically heterogeneous group of disorders characterized by the extracellular deposition of amyloid proteins in various tissues of the body. To date, 42 different amyloid proteins that originate from normal precursor proteins and are associated with distinct clinical forms of amyloidosis have been described. Identification of the amyloid type is essential in clinical practice, since prognosis and treatment regimens both vary according to the particular amyloid disease. However, typing of amyloid protein is often challenging, especially in the two most common forms of amyloidosis, i.e., the immunoglobulin light chain amyloidosis and transthyretin amyloidosis. Diagnostic methodology is based on tissue examinations as well as on noninvasive techniques including serological and imaging studies. Tissue examinations vary depending on the tissue preparation mode, i.e., whether it is fresh-frozen or fixed, and they can be carried out by ample methodologies including immunohistochemistry, immunofluorescence, immunoelectron microscopy, Western blotting, and proteomic analysis. In this review, we summarize current methodological approaches used for the diagnosis of amyloidosis and discusses their utility, advantages, and limitations. Special attention is paid to the simplicity of the procedures and their availability in clinical diagnostic laboratories. Finally, we describe new methods recently developed by our team to overcome limitations existing in the standard assays used in common practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
- Institute of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
- Institute of Nephrology and Hypertension, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
- Heart Failure Institute, Leviev Heart Centre, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.
- Multiple Myeloma Unit, Hematology Department, Sheba Medical Center, Ramat Gan 5262000, Israel.
ORCID-Profile: Batia Kaplan, Hila Magen, Amir Dori
Zitieren
APA
Goldis, R., Kaplan, B., Kukuy, O. L., Arad, M., Magen, H., Shavit-Stein, E., Dori, A., & Livneh, A. (2023). Diagnostic Challenges and Solutions in Systemic Amyloidosis. International Journal of Molecular Sciences, 24(5), 4655. https://doi.org/10.3390/ijms24054655
Vancouver
Goldis R, Kaplan B, Kukuy OL, Arad M, Magen H, Shavit-Stein E, et al. Diagnostic Challenges and Solutions in Systemic Amyloidosis. International Journal of Molecular Sciences. 2023;24(5):4655. doi:10.3390/ijms24054655
BibTeX
@article{Goldis2023,
author = {Goldis, Rivka and Kaplan, Batia and Kukuy, Olga Lesya and Arad, Michael and Magen, Hila and Shavit-Stein, Efrat and Dori, Amir and Livneh, Avi},
title = {Diagnostic Challenges and Solutions in Systemic Amyloidosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4655},
doi = {10.3390/ijms24054655}
}
EUVIMED